Akkermansia muciniphila reduces neuroinflammation and Aβ deposition via tryptophan metabolism in the APP/PS1 mouse model of Alzheimer's disease - PubMed
a day ago
- #Alzheimer's disease
- #Neuroinflammation
- #Gut microbiota
- Akkermansia muciniphila (A. muciniphila) improves cognitive deficits and reduces amyloid-beta (Aβ) deposition in APP/PS1 mice, a model for Alzheimer's disease (AD).
- Administration of A. muciniphila alters gut microbiota diversity and composition, increasing short-chain fatty acids (SCFAs) like butyric and acetic acid.
- Metabolomics show increased levels of 62 metabolites (e.g., indole-3-acetic acid, tryptophan) and decreased levels of 28 metabolites (e.g., isoleucine, N-acetylneuraminic acid) in treated mice.
- A. muciniphila reduces pro-inflammatory cytokines (IL-6, IL-1β, IL-17, TNF-α) and increases anti-inflammatory cytokines (IL-4, IL-10, IL-22) in plasma.
- Positive correlation found between increased metabolites (IAA, tryptophan, acetic acid) and cognitive function indicators.
- A. muciniphila alleviates neuroinflammation and Aβ deposition via the AhR/NF-κB/NLRP3 signaling pathway.
- Study suggests A. muciniphila as a potential therapeutic approach for AD via the microbiota-gut-brain axis.